Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Aerovate Therapeutics, Inc. (AVTE) stock rallied over 1.10% intraday to trade at $15.63 a share on NASDAQ. The stock opened with a gain of 5.54% at $15.15 and touched an intraday high of $17.19, rising 1.10% against the last close of $15.46. The stock went to a low of $14.6 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $15.15 | $17.19 | $14.6 | $15.63 | 64,554 |
2022-06-29 | $14.81 | $15.65 | $13.5 | $15.46 | 45,900 |
2022-06-28 | $15.24 | $15.85 | $14.21 | $14.97 | 46,400 |
2022-06-27 | $16.58 | $16.76 | $15.01 | $15.15 | 103,300 |
2022-06-24 | $13.6 | $16.95 | $13.1 | $16.55 | 575,400 |
2022-06-23 | $13.67 | $13.9 | $12.96 | $13.59 | 63,300 |
2022-06-22 | $12.32 | $14.5 | $12.27 | $13.5 | 101,700 |
2022-06-21 | $11.42 | $12.38 | $11.41 | $12.26 | 100,000 |
2022-06-17 | $12.21 | $13.35 | $11.88 | $12.18 | 99,000 |
2022-06-16 | $12.21 | $12.26 | $11.875 | $12.21 | 57,900 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) stock price is $15.63 as of the last check on Thursday, June 30. During the trading session, AVTE stock reached the peak price of $17.19 while $14.6 was the lowest point it dropped to.
The NASDAQ listed AVTE is part of Biotechnology industry that operates in the broader Health Care sector. Aerovate Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease.
Dr. Benjamin T. Dake Ph.D.
Founder, Pres, COO & Sec.
Mr. Hunter Gillies M.D.
Chief Medical Officer
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S
Chief Devel. Officer
Mr. Timothy P. Noyes M.B.A.
CEO & Director
AVTE stock traded closed the last session at $15.63, which is $0.17 or 1.10% lower than its previous close of $15.46. AVTE's current trading price is 101.94% lower than its 52-week high of $29.43 where as its distance from 52-week low of 7.74% is -46.89%.
Number of AVTE employees currently stands at -. AVTE operates from 930 Winter Street, Suite M-500, Waltham, MA 02116, United States.
Official Webiste of $AVTE is: https://aerovatetx.com
AVTE could be contacted at AVTE operates from 930 Winter Street, Suite M-500, Waltham, MA 02116, United States, or at phone #617 443 2400 and can also be accessed through its website.
AVTE stock volume for the day was 64,912 shares while in the previous session number of AVTE shares traded was 64,554 . The average number of AVTE shares traded daily for last 3 months was 73.84 Thousands.
The percentage change in AVTE stock occurred in the recent session was 1.10% while the dollar amount for the price change in AVTE stock was $0.17.
In the recent session, the day high for AVTE stock was $17.19 while the low for AVTE stock touched on the day was $14.6.
The market value of AVTE currently stands at 313.23 Million with its latest stock price at $15.63 and 24.41 Million of its shares outstanding.